Amiodarone monitoring: are existing guidelines outdated? In this interview, A. John Camm, MD, FACC and Uma Narasimhan Srivatsa MBBS, FACC, with Tiffany Y. Hu, MD, discuss Amiodarone monitoring in 2021.

Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

As the number of women of childbearing age with heart disease grows, the importance of safe and effective birth control counseling for pregnancy planning is more important than ever. Which contraceptive methods are optimal for women with cardiovascular disease?

In this interview, Kathryn J. Lindley, MD, FACC and Laxmi Mehta MD, FACC, with Lindsay Panah, MD, discuss Contraception and Reproductive Planning for Women with Cardiovascular Disease.

Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

This study investigates the efficacy and safety of finerenone, compared with a placebo to reduce clinically important cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes when added to the standard of care, which includes glucose-lowering therapies, and maximum-tolerated, labelled doses of either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker.

In this interview, Bertram Pitt, MD and Michelle L. O’Donoghue MD, FACC, with Michael Mikolaj MD, MPH, FACC, discuss ESC Late Breaker: FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes.

Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations.

In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients.

Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL

In this interview, Jeroen Bax, PhD, MD, FACC; Stefan Anker, MD, PhD; and Sherry-Ann Brown, MD, PhD, FACC, discuss the ESC Congress 2021 late breaker EMPEROR-Preserved, which evaluates the effect of empagliflozin for risk of cardiovascular death and hospitalisation for patients with heart failure and a preserved fraction with and without diabetes. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

In this interview, Michelle O’Donoghue, MD, FACC; John Teerlink, MD, FACC; and Jeffrey Hsu, MD, PhD, discuss the effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in the GALACTIC-HF trial. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

In this interview, Laxmi Mehta, MD, FACC, and Ole Frobert, MD, PhD, and discuss the ESC Congress 2021 late breaker IAMI. This study evaluates whether influenza vaccination improves outcomes in patients with recent MI. Influenza vaccine reduced the risk of the primary composite endpoint of all-cause death, MI, and stent thrombosis. Influenza vaccine also reduced two of the three key secondary endpoints. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

In this interview, Michelle Kittleson, MD, FACC, and Steffen Desch, MD, discuss the ESC Congress late-breaker TOMAHAWK, which examined whether immediate coronary angiography in survivors of out-of-hospital cardiac arrest and no ST-segment elevation is beneficial with regard to all-cause mortality at 30 days, compared with initial intensive care assessment with delayed/selective angiography. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

In this interview, Andrea Russo, MD, FACC; Marek Jastrzebski, MD, PhD; and Jeffrey Hsu, MD, PhD, focus on a Heart Rhythm Society late-breaking study on LBB optimized CRT, discussing its differences from traditional pacing and benefits to the patient, limitations of the alternative techniques, and a new method to more fully restore physiology of depolarization of the LV in patients with HF and broad QRS complex. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.

Geriatric principles impact the utility, performance, and interpretation of CV imaging tests. Considering geriatric principles can improve the patient experience during CV testing and the application of test results to clinical care. In this interview, Jeroen Bax, PhD, MD, FACC; Jim Kirkpatrick, MD, FACC; and Akhil Narang, MD, FACC, discuss the clinical utility and age-related challenges of CV imaging in older patients. Like what you hear? Get 20 episodes a month with CME/MOC credit at www.acc.org/ACCEL.